

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/734,847	12/12/2000	C. Frank Bennett	ISPH-0524	4732
26259	7590 08/22/2002			
LICATLA & TYRRELL P.C.			EXAMINER	
66 E. MAIN STREET MARLTON, NJ 08053			EPPS, JA	NET L
			ART UNIT	PAPER NUMBER
	•		1635	1 -
			DATE MAILED: 08/22/2002	10

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
•	09/734,847	BENNETT ET AL.				
Office Action Summary	Examiner	Art Unit				
	Janet L. Epps	1635				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1) Responsive to communication(s) fil	ed on					
2a) ☐ This action is FINAL .	2b) This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 1-33 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.	on and/or election requirement					
8)⊠ Claim(s) <u>1-33</u> are subject to restriction and/or election requirement. Application Papers						
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the estaglied Office action for a list of the position applies not received.						
* See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received.						
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)						
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (F 3) Information Disclosure Statement(s) (PTO-1449) P	PTO-948) 5) Notice of	Informal Patent Application (PTO-152)				

Application/Control Number: 09/734,847

Art Unit: 1635

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-13, and 17-33, drawn to a method of controlling the behavior of a cell

through modulation of the processing of a selected wild-type mRNA target

comprising modulation of splicing of said mRNA target, classified in class 435,

subclass 375.

II. Claims 1, 6, and 14-30, drawn to a method of controlling the behavior of a cell

through modulation of the processing of a selected wild-type mRNA target

comprising targeting the antisense compound to a sequence which controls the

stability of said mRNA target, classified in class 435, subclass 375.

The inventions are distinct, each from the other because of the following reasons:

2. The inventions of groups I and II are patentably distinct since they are drawn to distinct

methods comprising different method steps. Although, each method has the same objective,

namely for controlling the behavior of a cell through modulation of the processing of a selected

wild-type mRNA target, this objective is accomplished by entirely different means. For

example, the method according to group I comprise the use of antisense compounds that are

targeted to sequences associated with the splicing machinery of an mRNA target. In contrast, the

method according to group II comprises the use of antisense compounds that are targeted to

sequences that control the stability of an mRNA target, these sequences include those associated

with polyadenylation, and the regulation of RNA turnover or degradation. Since these methods

comprise the use of distinct antisense compounds targeted to entirely different sequences within

انخذ

Application/Control Number: 09/734,847 Page 3

Art Unit: 1635

an mRNA target, and having different modes of action and distinct chemical properties, the inventions of groups I-II are patentably distinct methods.

3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/734,847

Art Unit: 1635

Art Olit. 1033

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L Epps, Ph.D. whose telephone number is 703-308-8883. The examiner can normally be reached on M-T, Thurs-Friday 8:30AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on (703)-308-0447. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-746-5143 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Janet L Epp

Page 4

Art Unit 1635

JLE

August 18, 2002